In many urological cancers, ERK1/2, p38, β‐catenin, and E‐cadherin are involved in tumour transformation through the RAS/RAF/MEK/ERK or Wnt/β‐catenin pathways. This evidence concerns the gene MAPK1 and neoplasm.